Insmed unveils new research platforms and capabilities at investor and analyst event, "the future of rare at insmed: functional genes, ai-enhanced proteins, glowing algae, and more"

—early-stage research pillar anticipated to generate at least six investigational new drug (ind) applications by end of 2025— —company reveals select initial disease targets for next-generation gene therapies and deimmunized therapeutic proteins, including duchenne muscular dystrophy (dmd) and stargardt disease— —gene therapy clinical trial in dmd to be initiated in 2023, with data expected first half of 2024— —company announces $500,000 equity investment from cureduchenne ventures to support the development of a targeted gene therapy for dmd— bridgewater, n.j. , may 8, 2023 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced progress across its early-stage research programs, which will be discussed in greater detail this morning at the company's investor and analyst event, the future of rare at insmed: functional genes, ai-enhanced proteins, glowing algae, and more.
INSM Ratings Summary
INSM Quant Ranking